XANTHUS' SYMADEX SHOWS REMYELINATION IN PRECLINICAL MS STUDY

Xanthus Life Sciences has announced that data from a study conducted with a multiple sclerosis (MS) animal model demonstrated that Symadex permitted remyelination by prevention of inflammatory cell infiltration.

In the study, Symadex was found to produce remyelination in the study even after 40 days of inflammatory insult by preventing the infiltration of autoreactive cells into the central nervous system. Treatment proved to be effective in both the acute and chronic presentations of disease.